Istanbul, Turkey, 15th September 2009 – Further evidence of the superior antidepressant efficacy of Valdoxan®/Thymanax® (agomelatine) over conventional selective serotonin reuptake inhibitors (SSRIs) and serotonin noradrenalin reuptake inhibitor (SNRI) antidepressants was presented today at the Servier satellite symposium on the occasion of the 22nd European College of Neuropsychopharmacology (ECNP) Congress, with educational financial support provided [...]

1. NAME OF THE MEDICINAL PRODUCT
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
3. PHARMACEUTICAL FORM
4. CLINICAL PARTICULARS
4.1 Therapeutic indications
4.2 Posology and method of administration
4.3 Contraindications
4.4 Special warnings and precautions for use
[...]

1. What is the clinical proof of VALDOXAN’s antidepressant efficacy?
The antidepressant efficacy of VALDOXAN has been confirmed in four trials versus placebo, three over the short term and one over the long term. The antidepressant efficacy of VALDOXAN is significantly superior to that of placebo, as mentioned in the Valdoxan SPC, whatever the symptom intensity, [...]

Valdoxan, the first melatonergic antidepressant, presents an innovative receptor profile and mode of action. Valdoxan is a melatonergic agonist (MT1 and MT2 receptors) and 5-HT2C antagonist. Valdoxan resynchronizes circadian rhythms in animal models of circadian rhythm disruption.
Innovative receptor profile of Valdoxan
Valdoxan is the first melatonergic antidepressant.
Valdoxan is a melatonergic agonist (MT1 and MT2 receptors) and [...]